All In Biotech

Drug Trial Radar · NCT04806451

Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Pediatric Subjects With Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment

Last checked: Nov 19, 2026Latest source record: Feb 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 103 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

103

Actual

Start

Jun 25, 2021

Primary completion

Mar 10, 2023

Study completion Aug 2027

Sponsor

Lead sponsor
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
Sponsor type
Industry
First posted
Mar 19, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3 study to evaluate the efficacy, safety, and tolerability of crinecerfont versus placebo administered for 28 weeks in approximately 81 pediatric participants with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. The study consists of a 28-week double blind, placebo-controlled period, followed by 24 weeks of open-label treatment with crinecerfont. Subsequently, participants may elect to participate in the open-label extension (OLE) period. The duration of participation in the study is approximately 14 months for the core study and will be a variable amount of time per participant for the OLE (estimated to be approximately 3 years).

Conditions

  • Congenital Adrenal Hyperplasia

Interventions

  • CrinecerfontDrug

    CRF type 1 receptor antagonist

  • PlaceboDrug

    Non-active dosage form

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Serum Androstenedione at Week 4Time frame: Baseline, Week 4

Locations

46 sites in 10 countries. Site status is shown where the registry gives one.

  • Neurocrine Clinical Site

    Birmingham, Alabama

  • Neurocrine Clinical Site

    Los Angeles, California

  • Neurocrine Clinical Site

    Orange, California

  • Neurocrine Clinical Site

    San Diego, California

  • Neurocrine Clinical Site

    San Francisco, California

  • Neurocrine Clinical Site

    Aurora, Colorado

  • Neurocrine Clinical Site

    Hartford, Connecticut

  • Neurocrine Clinical Site

    Washington D.C., District of Columbia

  • Neurocrine Clinical Site

    Atlanta, Georgia

  • Neurocrine Clinical Site

    Indianapolis, Indiana

  • Neurocrine Clinical Site

    Boston, Massachusetts

  • Neurocrine Clinical Site

    Ann Arbor, Michigan

  • Neurocrine Clinical Site

    Minneapolis, Minnesota

  • Neurocrine Clinical site

    St Louis, Missouri

  • Neurocrine Clinical Site

    New Hyde Park, New York

  • Neurocrine Clinical Site

    New York, New York

  • Neurocrine Clinical Site

    Oklahoma City, Oklahoma

  • Neurocrine Clinical Site

    Tulsa, Oklahoma

  • Neurocrine Clinical Site

    Philadelphia, Pennsylvania

  • Neurocrine Clinical Site

    Pittsburgh, Pennsylvania

  • Neurocrine Clinical Site

    Dallas, Texas

  • Neurocrine Clinical Site

    Seattle, Washington

  • Neurocrine Clinical Site

    Brussels, Belgium

  • Neurocrine Clinical Site

    Ghent, Belgium

  • Neurocrine Clinical Site

    Edmonton, Alberta, Canada

  • Neurocrine Clinical Site

    Vancouver, British Columbia, Canada

  • Neurocrine Clinical Site

    Montreal, Quebec, Canada

  • Neurocrine Clinical Site

    Angers, France

  • Neurocrine Clinical Site

    Bordeau, France

  • Neurocrine Clinical Site

    Le Kremlin-Bicêtre, France

  • Neurocrine Clinical Site

    Paris, France

  • Neurocrine Clinical Site

    Paris, France

  • Neurocrine Clinical Site

    Berlin, Germany

  • Neurocrine Clinical Site

    Heidelberg, Germany

  • Neurocrine Clinical Site

    Magdeburg, Germany

  • Neurocrine Clinical Site

    Athens, Greece

  • Neurocrine Clinical Site

    Athens, Greece

  • Neurocrine Clinical Site

    Bologna, Italy

  • Neurocrine Clinical Site

    Milan, Italy

  • Neurocrine Clinical Site

    Naples, Italy

Showing 40 of 46 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.